High potency silencing by single-stranded boranophosphate siRNA

Allison H. S. Hall¹, Jing Wan², April Spesock¹, Zinaida Sergueeva², Barbara Ramsay Shaw² and Kenneth A. Alexander¹,³,*

¹Department of Molecular Genetics and Microbiology, Box 3020, Duke University Medical Center, Durham, NC 27710, USA, ²Department of Chemistry, Box 90354, Duke University, Durham, NC 27708, USA and ³Department of Pediatrics, Section of Pediatric Infectious Diseases, The University of Chicago, 5841 S. Maryland Ave., MC 6054, Chicago, IL, 60637, USA

Received January 30, 2006; Revised February 15, 2006; Accepted April 17, 2006

ABSTRACT

In RNA interference (RNAi), double-stranded short interfering RNA (ds-siRNA) inhibits expression from complementary mRNAs. Recently, it was demonstrated that short, single-stranded antisense RNA (ss-siRNA) can also induce RNAi. While ss-siRNA may offer several advantages in both clinical and research applications, its overall poor activity compared with ds-siRNA has prevented its widespread use. In contrast to the poor gene silencing activity of native ss-siRNA, we found that the silencing activity of boranophosphate-modified ss-siRNA is comparable with that of unmodified ds-siRNA. Boranophosphate ss-siRNA has excellent maximum silencing activity and is highly effective at low concentrations. The silencing activity of boranophosphate ss-siRNA is also durable, with significant silencing up to 1 week after transfection. Thus, we have demonstrated that boranophosphate-modified ss-siRNA can silence gene expression as well as native ds-siRNA, suggesting that boranophosphate-modified ss-siRNAs should be investigated as a potential new class of therapeutic agents.

INTRODUCTION

RNA interference (RNAi) is a form of post-transcriptional gene silencing in which double-stranded RNA (dsRNA) targets complementary mRNAs for destruction [reviewed in (1–4)]. RNAi occurs in a wide variety of organisms, ranging from protozoa to mammals. There has been considerable interest in harnessing the power of RNAi to treat human diseases such as viral infections (5,6), cancer (7,8) and sepsis (9). While questions remain about the precise mechanism of RNAi, recent work has provided a clearer understanding of the process. In the endogenous RNAi system, the effector molecule is a double-stranded short interfering RNA (ds-siRNA) ~21 bp in length with 3’ dinucleotide overhangs (10). ds-siRNAs associate with Argonaute family proteins to form an RNA induced silencing complex (RISC) (11,12). One of the strands of the ds-siRNA is removed or destroyed and only a single strand remains in the mature RISC (13–16). The complex then targets mRNA complementary to the incorporated strand (13). Thus, it is the antisense strand of the ds-siRNA that targets a particular mRNA for destruction.

Several studies have shown that it is possible to bypass the dsRNA stage by introducing single-stranded antisense RNA ~21 bases long into RNAi-competent cells or cell lysates (13,17,18). These single-stranded siRNA (ss-siRNA) molecules have several advantages over the standard, ds-siRNA, particularly in the context of potential clinical applications. First, as only one RNA strand is needed, the cost and work of preparation is reduced by half. Single-stranded molecules may also avoid one of the major obstacles to therapeutic use of ds-siRNA: unintended side effects. For example, a recent study showed that both chemically and enzymatically synthesized ds-siRNA species induced interferon expression, whereas none of the ss-siRNA species provoked a detectable interferon response (19). Off-target silencing of genes with similar but non-identical sequences to the sense or antisense strand is another potential obstacle to the specificity of siRNA activity (20). By using a single strand, the risk of off-target silencing guided by the sense strand is eliminated. Finally, ss-siRNAs may circumvent the RNAi-suppressing activity of ds-RNA-binding proteins (21,22).

Despite these potential advantages of ss-siRNAs, the single-stranded molecule has a significant shortcoming; ss-siRNAs do not efficiently induce RNAi. ss-siRNA must
be used at concentrations that are 6- to 100-fold higher than that of ds-siRNA to achieve comparable levels of gene silencing (13,17,18). The reason for the poor silencing activity of the single-stranded molecules is not yet known.

To investigate whether the low level of silencing by ss-siRNAs could be improved, we sought to examine the activity of ss-siRNAs with the boranophosphate (BP) backbone modification. We have shown previously that BP-modified ds-siRNAs are more active for gene silencing than the corresponding phosphodiester- or phosphorothioate-backbone ds-siRNAs (23). In the boranophosphate (BP) linkage (Figure 1A), a non-bridging phosphodiester oxygen is replaced with an isoelectronic borane (–BH₃/C0) moiety. BP nucleic acids maintain the ability to base pair with high specificity and affinity and BP nucleotides can be readily incorporated into DNA and RNA molecules by DNA and RNA polymerases, permitting synthesis of stereoregular boranophosphate oligonucleotides (23–28). The boranophosphate modification appears to be well tolerated in mammalian systems; BP ds-siRNAs do not induce any appreciable toxicity in HeLa cells (23). Furthermore, BP DNA dinucleotides are minimally toxic to rodents, and the degradation product of BP oligonucleotides (borate) is minimally toxic to humans (23,29,30).

In this work, we demonstrate that partial BP-modification increases the silencing activity of ss-siRNA against green fluorescent protein in HeLa cells. In our system single-stranded BP-siRNAs can silence gene expression as well as native ds-siRNA.

MATERIALS AND METHODS

Synthesis of boranophosphate siRNAs

ss- and dsRNA molecules were synthesized as described previously (23). Briefly, DNA oligonucleotides were purchased from Qiagen: T7 promoter primer, 5'-TAATACGACTCACTATAG-3'; EGFP1 templates: sense, 5'-AAGTTCCACTATAGTGAGTCGTATTA-3' and antisense, 5'-AAGAACGGCATCAAGGTGAACTATAGTGAGTCGTATTA-3'; control EGFP1 templates: sense, 5'-AAGTTCCACCTATAGTGAGTCGTATTA-3' and antisense, 5'-AAGAACGGATGTTAGTTCCGTTCTATAGTGAGTCGTATTA-3'; EGFP2 templates: sense, 5'-AAGGACTTCTCAGGATGCTGTAGTGAGTCGTATTA-3' and antisense, 5'-AAGGACTTCTCAGGATGCTGTAGTGAGTCGTATTA-3'; Control EGFP2 templates: sense, 5'-AAGGACTTCTCAGGATGCTGTAGTGAGTCGTATTA-3' and antisense, 5'-AAGGACTTCTCAGGATGCTGTAGTGAGTCGTATTA-3'; ssRNA molecules were synthesized using T7 RNA polymerase. To create boranophosphate modified oligonucleotides, one or more ribonucleoside 5'-((α-P-boranophosphate)riphosphates were added to the transcription reaction in place of the corresponding rNTPs. RNAs were then purified as single strands using phenol extraction and Microspin G-50 Micro Columns (Amersham) or PAGE and suspended in water. To make dsRNA, sense and antisense strands were first annealed and then purified and concentrated using Microcon YM-10 centrifugal filters (Millipore). RNA concentration was determined by UV absorbance at 260 nm.

Cell culture and transfection

EGFP-TRex HeLa cells, which express enhanced green fluorescent protein (EGFP) under control of a tetracycline responsive promoter, were cultured as described previously (23).
Twenty-four hours after plating, cells were transfected with siRNA using Oligofectamine (Invitrogen) according to the manufacturer’s instructions with 1.35 μl Oligofectamine per well of a 24-well plate. The concentration of siRNA in the cell culture medium ranged from 3.1 to 50 nM, as described in figure legends. Twenty-four hours after siRNA transfection, cells were induced to express EGFP with 1 μg/ml tetracycline. For the EGFP1 control sequence, the six central nucleotides of the active EGFP1 sequence were inverted. As the control sequence for EGFP2, we used an siRNA in which the eight central nucleotides inverted because the sequence with six inverted nucleotides had an unacceptable degree of homology to some human mRNAs.

Flow cytometry analysis

Cells were trypsinized and fixed in 1% formaldehyde in phosphate-buffered saline, 48 h post-transfection. Cells were analyzed for EGFP expression using a FACScan (Becton-Dickinson) flow cytometer. Data were processed using CellQuest software (Becton-Dickinson).

Cellular RNA analysis

Cells were transfected in culture medium at a final siRNA concentration of 12.5 nM. EGFP1 production was induced with 1 μg/ml tetracycline. Cells were trypsinized and total cytoplasmic RNA isolated using the RNeasy kit (Qiagen), 22 h after EGFP induction. RNA from each sample (2 μg) was separated by formaldehyde–agarose gel electrophoresis, transferred to a positively charged nylon membrane and was separated by formaldehyde–agarose gel electrophoresis, hybridized with 32P-labeled RNA probes complementary to crosslinked by UV irradiation. The immobilized RNA was transferred to a positively charged nylon membrane and was separated by formaldehyde–agarose gel electrophoresis, hybridized with 32P-labeled RNA probes complementary to crosslinked by UV irradiation. The immobilized RNA was hybridized with 32P-labeled RNA probes complementary to the EGFP coding sequence and to human β-actin (to normalize for signal). Hybridization was quantified using a Molecular Dynamics phosphorimaging system.

Quantitative RT–PCR

Cells were transfected in culture medium at a final siRNA concentration of 25 nM or mock transfected with Oligofectamine (Invitrogen) alone. Cells were trypsinized and total cytoplasmic RNA isolated using the RNeasy kit (Qiagen), 24 h after transfection. RNA from each sample (1 μg) was used to make cDNA using the iScript kit (Bio-Rad). Quantitative PCR was performed using SYBR Green I (Invitrogen), Platinum Taq (Invitrogen), 1.5 mM MgCl2 and primers at a concentration of 0.2 μM. PCR was performed on a Roche Lightcycler and data were analyzed using Lightcycler software. The following primers were used: human Ago2, 5'-TGGCTGTG- CTTTGTTAAAAACGCT-3' and 5'-CGGCTCGAAGGGACTGC- TCTA-3'; human GAPDH, 5'-CATGTTCGTCATGGGTGTG- and 5'-CGCGTCCGAAGGCTGCG-; human β-actin, 5'-AGTGTGGGATGGATGGTAT-3' and 5'-AGTGTGGGATGGATGGTAT-3'.

RNase susceptibility analysis

EGFP1 and EGFP2 RNAs (10 pmol) were incubated with 0.5 and 2 ng RNase A (Roche), respectively, in 5 μl RNase reaction buffer (10 mM Tris–HCl, pH 7.5, 1 mM EDTA and 150 mM NaCl) at 37°C for specified lengths of time. The RNase reactions were stopped by adding 2 vol of the gel-loading buffer (10 M urea, 50 mM EDTA, 0.1% bromophenol blue and 0.1% xylene cyanol), and loaded on a 4% agarose gel. After SYBR Gold (Molecular Probes) staining, the gels were photographed under UV illumination and analyzed using Fluorescent Image Analytical Software (Hitachi Software Engineering Co. Ltd).

RESULTS
ds-siRNAs and several species of ss-siRNAs, all targeting EGFP, were synthesized as described previously (23) (Figure 1). Briefly, all RNA species were synthesized using T7 RNA polymerase and purified as single strands. To create BP-modified siRNAs, one or more native ribonucleoside triphosphate was replaced by its BP counterpart in the transcription reaction.

Silencing activity of native and BP ss-siRNA

Native and BP ss-siRNAs targeted to EGFP were tested for silencing activity in HeLa cells that express EGFP under control of a tetracycline-inducible promoter. For these studies, cells were transfected with ds- or ss-siRNA, induced to express EGFP, and then, after 24 h, analyzed by flow cytometry to measure the level of EGFP protein expression. The fluorescence of cells transfected with siRNA was compared with the fluorescence of mock-transfected cells (treated with Oligofectamine alone) to determine the percent inhibition of EGFP expression. To control for non-specific effects of the RNA, we tested control sequence ss-siRNAs with the central 6 or 8 nt inverted (Figure 1B). None of the control ss-siRNAs silenced EGFP expression (Figure 2).

Initially, EGFP1 sequence ss-siRNAs were tested at a concentration of 25 nM because this is the concentration at which silencing by native ds-siRNA approaches a maximum, thereby allowing comparison of the peak silencing activity of...
the different siRNAs. Similar to earlier studies (13,17,18), we
found that native ss-siRNA could inhibit EGFP expression,
but was significantly less active than native ds-siRNA
(Figure 2A). When BP-modified siRNAs were studied, we
found that ss-siRNA with BP-modified cytidine residues
(A\text{b}\text{c}) silenced EGFP expression with the same efficiency
as the unmodified ds-siRNA. Furthermore, an anti-EGFP
ss-siRNA with modified adenosine and cytidine residues
was significantly more active than native ds-siRNA (99% versus 70% reduction in EGFP expression, respectively).

While BP modification of cytidine and adenosine resi-
dues significantly enhanced silencing activity of ss-siRNAs,
ss-siRNAs that included modified uridines (A\text{b}\text{c} and A\text{c})
were notably less active than unmodified ss-siRNA. There-
fore, we examined why these species had reduced EGFP
silencing activity. We have demonstrated previously in ds-
siRNAs that a high proportion of BP residues in the center
of the antisense strand reduces siRNA silencing activity
(23). As there are four uridine residues among the central
six nucleotides (those that surround the predicted target
cleavage site, Figure 1B) in the EGFP1 sequence, the
reduced silencing activities of A\text{b}\text{c} and A\text{c} were consistent
with the pattern established previously with ds-siRNAs,
and suggest that modification of the central bases of ss-
siRNAs reduces silencing activity in a manner analogous
to the reduction seen with modification of the central
bases of double-stranded BP-siRNAs.

While we suspected that extensive modification of central
nucleotides caused the reduction in siRNA silencing, the loss
of activity in ss-siRNAs with modified uridines could also
have been due to modification of the two residues on the
3' end, or simply due to the presence of modified uridines.
To further examine the relationship between modification
sites and ss-siRNA activity, a different anti-EGFP sequence
(EGFP2) was tested. This sequence has two uridines at the
3' end; however, none of the six central nucleotides are
uridines. Instead, there are four adenosines in this region
(Figure 1B). Once again, the native ss-siRNA had a much
lower level of silencing activity than native ds-siRNA
(Figure 2B). However, BP-modification of the uridine resi-
dues (all peripheral) caused a dramatic increase in
ss-siRNA activity, almost restoring it to the level of ds-
siRNA. In contrast, when adenosine residues were modified
in the EGFP2 molecule (resulting in modification of 3 of
the central 6 nt), activity remained at a low level. These
results demonstrate that BP-modified uridine residues
and 3' overhangs are compatible with ss-siRNA activity
and provide additional support for the hypothesis that multiple
central BP modifications interfere with efficient silencing.

The overall pattern of increased activity with peripheral
modification and reduced activity with central modification
was consistent for both anti-EGFP sequences. However, in
contrast to the results for EGFP1 ss-siRNAs, increasing the
degree of peripheral BP modification in EGFP2 ss-siRNAs
caused a slight decrease in silencing activity (Figure 2B,
A\text{b}\text{c} and A\text{c}).

Dose response of native and BP ss-siRNA

We determined silencing dose response curves for several
anti-EGFP1 siRNAs (Figure 3). As we had observed when
a single siRNA concentration was used, the double-stranded
native A\text{b}\text{c} siRNA exhibited moderate silencing activity.
A\text{b}\text{c} induced an ~80% reduction in EGFP fluorescence at
50 nM siRNA and had half maximal silencing activity in
the range of 2 nM. In contrast, A\text{c} silences EGFP expression
only modestly, inducing only ~60% silencing at 50 nM with
half maximal silencing at ~15 nM. When BP cytidine resi-
dues are introduced to the EGFP1 ss-siRNA, its activity
improves such that the dose response curve of A\text{b}\text{c}
is almost identical to that of A\text{b}\text{c}. When modified cytidine and
adenosine residues are used, silencing activity of the ss-siRNA
becomes highly active; A\text{b}\text{c} induces close to 100% EGFP
silencing at 25 nM, with half-maximal silencing induced at
~1 nM siRNA.

Kinetics of silencing by native and BP ss-siRNA

Next, we examined the effect of BP modification on
ss-siRNA silencing over time. HeLa cells were transfected
with siRNA, induced to express EGFP after 5 h or after 1,
3, 5 or 7 days and fixed 24 h after induction. To assess the
duration of silencing relative to each interfering RNA’s ac-
ivity, the level of silencing after 1 day was normalized to 100.
While the activity of all RNA species starts to decline after
3 days, the activity of native ss-siRNA (A\text{c}) declines much
more quickly than that of native ds-siRNA (A\text{b}\text{c}) or BP
ss-siRNAs (A\text{b}\text{c} and A\text{b}\text{c}) (Figure 4). It should be noted that the
raw data reveal that, consistent with our other results, native
ss-siRNA was significantly less active than native ds-siRNA
and that modified ss-siRNAs were active (A\text{b}\text{c}) or more
active (A\text{b}\text{c} and A\text{b}\text{c}) than native ds-siRNA at all times tested (data
not shown). Notably, the raw data also reveal that A\text{b}\text{c}
still reduced EGFP expression by ~50% 1 week after trans-
fection. Finally, while other investigators have reported that
ss-siRNA achieves maximum silencing more quickly than
ds-siRNA (18), we did not observe such a pattern.
BP ss-siRNA silences by reducing target mRNA levels

siRNAs inhibit protein expression primarily by inducing cleavage of target mRNA. However, it has also been shown that some RNA species, known as miRNAs, can silence genes by inhibiting translation of their targets (31). Previous work suggests that the presence of a base mismatch or a bulge when the siRNA pairs with its target can cause it to function through the miRNA pathway rather than by the RNAi mechanism (32). Because miRNAs have been shown to function as single strands (33), we investigated whether BP ss-siRNAs might act by inhibiting translation of target mRNA. The effects of BP ss-siRNA and native ds-siRNA on EGFP mRNA levels were examined by northern blot and were normalized to β-actin expression. Similar to ds-siRNA, BP-modified ss-siRNA caused a reduction in the level of EGFP mRNA (Figure 5A). To compare the relative change in protein and mRNA levels, samples of the cells used for northern analysis were analyzed by flow cytometry. If the BP ss-siRNA inhibited translation in addition to reducing mRNA levels, it should cause a relatively greater protein inhibition than mRNA inhibition, compared with unmodified ds-siRNA. Instead, for both native ds-siRNA and BP ss-siRNA, the percent inhibition of protein expression closely matches the percent inhibition of mRNA expression (Figure 5B). Furthermore, the ratios of the reductions in protein levels to the reductions in mRNA levels are the same for BP ss-siRNA and native ds-siRNA. We therefore conclude that modified ss-siRNAs inhibit protein expression primarily by reducing EGFP mRNA levels, rather than by inhibiting translation.

BP ss-siRNA activity requires Argonaute2 expression

Having determined that BP ss-siRNA silence protein expression by mRNA cleavage, we further examined the process of silencing by these molecules. Previous work has suggested that native ss-siRNA act through the RISC to induce RNAi (13,17,18). However, in all of these studies, the concentrations of ss-siRNA required to achieve gene silencing comparable with that induced by ds-siRNA were 6- to 100-fold higher. Therefore, it is important to determine whether the highly efficient silencing observed with BP ss-siRNA is due to RISC-related activity or to engagement of a different gene silencing mechanism, such as induction of degradation by a double-stranded RNase (34). To determine the RISC-dependence of BP ssRNA silencing, we examined the effect of siRNAs that have been shown to knock-down expression of Argonaute2 (Ago2), a key component of the RISC (35). For these studies, EGFP-HeLa cells were transfected with Ago2 siRNA or with control, non-silencing siRNA. The cells were transfected with native ds-siRNA (which is known to interact with the RISC) or BP ss-siRNA targeted to EGFP, 24 h later. Cells were induced to express EGFP 24 h after the second transfection and analyzed by flow cytometry 24 h after induction. It has been demonstrated previously that when RISC is disrupted by knocking-down Ago2 expression, silencing by ds-siRNA is eliminated (35). If BP ss-siRNA acts through a RISC-dependent process, its silencing activity should be also dramatically reduced when Ago2 is silenced.
The siRNA targeted to Ago2 caused a notable reduction in Ago2 expression as measured by quantitative RT–PCR (Figure 6A). We found that when Ago2 expression was suppressed, the ability of native ds-siRNA to silence EGFP expression was reduced dramatically, compared with cells initially transfected with control siRNA (Figure 6B). The silencing activity of BP ss-siRNA was abrogated to a similar extent by Ago2 silencing, indicating that BP ss-siRNA acts primarily through a RISC-dependent process (Figure 6B). To ensure that inhibiting Ago2 expression does not, by itself, affect EGFP expression, we also examined cells transfected with Ago2 siRNA, followed by control siRNA. The Ago2 siRNA did not appreciably affect EGFP expression; mean fluorescence for mock transfected and Ago2 transfected cells were 537.1 and 536.1, respectively (in arbitrary units). The combination of the northern blot and the Ago2 knock-down data suggests that BP ss-siRNA acts primarily through the standard RNAi pathway used by ds-siRNA.

Figure 6. Silencing by boranophosphate ss-siRNA is Ago2-dependent. (A) Cells we mock-transfected with Oligofectamine alone (mock) or transfected with control ds-siRNA (control) or ds-siRNA targeted to Ago2 (Ago2). Ago2 mRNA levels were measured by quantitative RT–PCR and normalized to GAPDH mRNA levels. (B) Cells were transfected with control ds-siRNA (closed bars) or ds-siRNA targeted to Ago2 (gray bars). Twenty-four hours later, cells were retransfected with control ds-siRNA, EGFP1 native ds-siRNA (A°S°) or EGFP1 BP ss-siRNA (A°Bac). EGFP fluorescence was measured by flow cytometry. Data were normalized with silencing by anti-EGFP siRNAs after initial transfection with control siRNA set at an arbitrary value of 100. Error bars represent standard error.

BP-modification has variable effects on ss-siRNA nuclease resistance

Having demonstrated that the BP modification dramatically improves the silencing activity of ss-siRNAs, we sought to examine the reason for this change in activity. Given the susceptibility of ssRNA to RNases and the enhanced nuclease stability of BP-modified dsRNA (23), we initially speculated that the enhanced silencing activity of BP ss-siRNAs was at least partially due to their greater resistance to RNase degradation. To test this hypothesis, we examined the susceptibility of native and BP ss-siRNAs to degradation by RNase A. As expected, unmodified ss-siRNA was very susceptible to nuclease digestion while ds-siRNA was relatively resistant to degradation (Figure 7). Boranophosphate modification did enhance nuclease resistance of some ss-siRNA species. However, BP modification did not result in a consistent improvement in nuclease stability, nor did resistance to RNase degradation correlate with greater silencing activity. Notably, the most active siRNA we tested, the EGFP1 ss-siRNA with modified adenosine and cytosine residues, was degraded at essentially the same rate as the native ss-siRNA. This result suggests that nuclease resistance may not be the sole reason for the enhanced silencing activity of BP ss-siRNAs.

DISCUSSION

ssRNA can efficiently induce RNAi

While testing the silencing activity of native and boranophosphate modified ss- and ds-siRNAs, we discovered that BP ss-siRNA can be a highly effective gene silencing tool. As seen in several previous studies (13,17,18), we found that the gene silencing activity of unmodified ss-siRNA was substantially less than that of ds-siRNA. In contrast, we found that the most effective BP-modified ss-siRNA species (EGFP1 A°Bac with modified adenosine and cytidine residues)
is even more active than native ds-siRNA, implying that ss-siRNA can be efficiently incorporated into the RISC (Figures 2 and 3). The maximum activity of \( A_{ac}^{bol} \) is also greater than that of any BP-modified ds-siRNA that we have examined (data not shown) (23). To our knowledge, this is the first demonstration that the silencing activity of ssRNA can match or exceed that of dsRNA. Also, given our findings that BP ss-siRNA silencing is due to a reduction in mRNA levels and is Argonaute2-dependent, it seems likely that BP ss-siRNA acts through the standard RNAi pathway.

Structure-activity relationships in BP ss-siRNA

We found that position effects of BP modifications followed the same general rule we discerned when testing BP-modified dsRNA (23): peripheral BP modification is well tolerated, while central modifications cause a significant loss of activity. However, the magnitude of the benefit of peripheral BP modification was greater when applied to single-stranded molecules. At 25 nM, peripheral modification of ss-siRNA caused up to a 2.4-fold increase in silencing activity (Figure 2, \( A_{ac}^{bol} \)), compared with a maximum increase in ds-siRNA activity of 1.3-fold (23).

Because peripheral modifications dramatically increase ss-siRNA silencing activity, we initially hypothesized that the positive attributes conferred by central modifications would offset their inhibitory effects, such that even central modifications would enhance activity. Instead, ss-siRNA species with central modifications have activity levels that are as low as or lower than those of native ss-siRNA (Figure 2). Apparently, the unfavorable effects of central modification are still significant in single-stranded molecules. The poor activity of centrally modified ds-siRNA and ss-siRNA may reflect a disruption of the enzymatic activity of the RISC, which cleaves the target directly across from the center of the interfering RNA (36). Previous studies have demonstrated that central sequence mismatches or ribose modifications inhibit ds-siRNA activity (36,37), although the regions that are sensitive to such changes appears to be more extensive than the area that is sensitive to BP modification.

Mechanisms of enhanced activity in boranophosphate ss-siRNAs

We initially hypothesized that BP-modified ss-siRNAs would be more nuclease resistant that native ss-siRNA and that this would be a major reason for their enhanced silencing activity. However, we found that BP modification did not consistently result in greater resistance to RNase A digestion for the sequences tested here. Indeed, the BP ss-siRNA species with the greatest silencing activity (EGFP1 \( A_{ac}^{bol} \)) was degraded at essentially the same rate as native ss-siRNA (Figure 7). It is still possible that BP modification could confer greater stability within the cell or in the culture medium; RNase A resistance may not directly correlate with resistance to other nucleases. However, the absence of an observable increase in RNase stability with BP modification suggests that the enhanced activity of BP ss-siRNAs may not be solely due to improved nuclease resistance. This hypothesis is supported by other work showing that modifications that confer nuclease resistance do not necessarily enhance the activity of ds- or ss-siRNAs (37,38).

Instead, we suspect that BP ss-siRNAs have other advantageous properties that confer efficient silencing activity. Borane substitution of a non-bridging oxygen results in changes in size, charge, polarity and stereochemistry (39). It can be imagined that the presence of a borane group instead of oxygen in the phosphate backbone of RNA would change their interaction with other molecules, e.g. mRNA target and RISC protein components. Indeed, we have found recently that BP modification raises the melting temperature of siRNAs, suggesting that a modified siRNA might have a greater affinity for the target mRNA than a native siRNA (40). Another characteristic of BP siRNA that may enhance its silencing activity is its tendency to make an A-form helix (40). The results of several different studies suggest that efficient cleavage of the target RNA requires the A-form structure between the guide strand of the ds-siRNA and the target (37,41,42). Investigations of the interactions between BP ss-siRNA and RISC should facilitate mechanistic understanding of RNAi and may suggest generally applicable strategies for enhancing siRNA activity.

Therapeutic potential of boranophosphate ss-siRNAs

Our examination of silencing by boranophosphate-modified ss-siRNA suggests that BP ss-siRNA could have significant therapeutic potential. The high maximum activity, potency at low concentrations and duration of silencing by EGFP1 \( A_{ac}^{bol} \) suggest that relatively low and infrequent dosing of BP ss-siRNA could be effective, even in rapidly dividing cells. Indeed, by accounting for dilution by cell division and comparing the activity over time to dose response curves, it appears that essentially all of the decline in activity can be accounted for by this dilution. Therefore, we expect that silencing would last even longer in non-dividing cells or when the siRNA blocks cell growth (7).

In addition to its excellent silencing activity, BP ss-siRNA has advantages unique to ssRNA: simplified synthesis and no risk of off-target silencing by the sense strand. Furthermore, the smaller size and reduced negative charge of ss-siRNA may facilitate delivery into cells. We also believe that ssRNA is less likely to induce an interferon response than dsRNA. Most examinations of interferon induction by siRNAs have shown that ss-siRNAs do not provoke an interferon response (19). However, a recent publication reported that ssRNA synthesized by phage polymerases (the method used here) can induce interferon expression due to the presence of 5’ triphosphate groups (43). In the context of potential clinical applications, this should not pose a significant problem because the terminal phosphates can be easily removed by calf intestinal alkaline phosphatase treatment (43). Because control sequence siRNAs (also synthesized by T7 polymerase) did not show any silencing activity (Figure 2), we do not believe that our analysis of silencing activity was affected by the presence of 5’ triphosphate groups on the siRNAs we tested.

The use of single-stranded molecules may be particularly desirable in specific situations. For example, BP ss-siRNAs may permit the use of sequences whose sense strand sequence would be nearly complementary to other (off-target) human genes. In addition, the ability to use single-stranded molecules should enhance silencing by sequences that would
otherwise have poor activity due to incorporation of the inactive sense strand into the RISC [it should be noted that other strategies to favor incorporation of the active strand have also been developed (44)]. This relaxation of sequence requirements is likely to be especially important when there are relatively few potential sequences, such as when the target is a particular splice variant or mRNA with a specific point mutation. ss-siRNAs are also likely to be useful in treating viral infections because many human viruses express dsRNA-binding proteins, presumably to evade the host cell interferon response (21,22).

CONCLUSION

We have shown that boranophosphate modified ss-siRNA efficiently induces silencing at high and low concentrations and for extended periods of time. This finding is significant, because it demonstrates that, when appropriately modified, ss-siRNA can induce RNAi at least as effectively as ds-siRNA. It also introduces a new category of molecules for potential use as RNAi-based therapeutics.

ACKNOWLEDGEMENTS

We would like to thank Danuta Gasinski and the Duke University Cancer Center Cell Culture and Flow Cytometry facilities for excellent technical assistance. This work was supported by a grant from The Children’s Miracle Network (K.A.A.), NIH R01 CA108124 (K.A.A.), NIH R21 CA104604-01 (K.A.A. and B.R.S.), Department of Defense Grant DAMD 17-02-1-0376, sponsored by the Department of the Army (B.R.S.), NIH R01 GM57693 (B.R.S.) and the Duke University Medical Scientist Training Program (A.H.S.H). The content of the information does not necessarily reflect the positions or the policy of the Government, and no official endorsement should be inferred. Funding to pay the Open Access publication charges for this article was provided by the Section of Pediatric Infectious Diseases, the University of Chicago.

Conflict of interest statement. None declared.

REFERENCES

1. Denli, A.M. and Hannon, G.J. (2003) RNAi: an ever-growing puzzle. Trends Biochem. Sci., 28, 196–201.
2. Novina, C.D. and Sharp, P.A. (2004) The RNAi revolution. Nature, 430, 161–164.
3. Meister, G. and Tuschl, T. (2004) Mechanisms of gene silencing by double-stranded RNA. Nature, 431, 343–349.
4. Hutvagner, G. and Zamirote, P.D. (2002) RNAi: nature abhors a double-strand. Curr. Opin. Genet. Dev., 12, 225–232.
5. Coburn, G.A. and Cullen, B.R. (2002) Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol., 76, 9225–9231.
6. Randall, G., Grakoui, A. and Rice, C.M. (2003) Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl Acad. Sci. USA, 100, 235–240.
7. Hall, A.H. and Alexander, K.A. (2003) RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol., 77, 6066–6069.
8. Wilda, M., Fuchs, U., Wossmann, W. and Borkhardt, A. (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene, 21, 5716–5724.
9. Sorensen, D.R., Leidm, M. and Sioud, M. (2003) Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol., 327, 761–766.
10. Elbashir, S.M., Lendeckel, W. and Tuschl, T. (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev., 15, 188–200.
11. Hammond, S.M., Bernstein, E., Beach, D. and Hannon, G.J. (2000) An RNA-directed nuclease mediates post-transcriptional genetic silencing in Drosophila cells. Nature, 404, 293–296.
12. Hammond, S.M., Boettcher, S., Caudy, A.A., Kobayashi, R. and Hannon, G.J. (2001) Argonaute2, a link between genetic and biochemical analyses of RNAi. Science, 293, 1146–1150.
13. Martinez, J., Patkanowiska, A., Urlaub, H., Luhmann, R. and Tuschl, T. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 110, 563–574.
14. Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. and Zamore, P.D. (2005) Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell, 123, 607–620.
15. Rand, T.A., Petersen, S., Du, F. and Wang, X. (2005) Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 123, 621–629.
16. Leuschner, P.J., Ameres, S.L., Kueng, S. and Martinez, J. (2006) Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep., 7, 314–320.
17. Schwartz, D.S., Hutvagner, G., Haley, B. and Zamore, P.D. (2002) Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell, 10, 537–548.
18. Holen, T., Amarguizouli, M., Babaei, E. and Prydz, H. (2003) Similar behavior of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res., 31, 2401–2407.
19. Slezak, C.A., Holko, M., van De Veer, M.J., Silverman, R.H. and Williams, B.R. (2003) Activation of the interferon system by short-interfering RNAs. Nature Cell Biol., 5, 834–839.
20. Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G. and Linsley, P.S. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 21, 635–637.
21. Li, W.X., Li, H., Lu, R., Li, F., Dus, M., Atkinson, P., Brydon, E.W., Johnson, K.L., Garcia-Sastre, A., Barila, O. and et al. (2004) Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc. Natl Acad. Sci. USA, 101, 1350–1355.
22. Meraif, Z., Kerényi, Z., Molnár, A., Barta, E., Valoczi, A., Bisztray, G., Ledbetter, A., Hulveyda, Z., Burgyan, J. and Silhavy, D. (2005) Aurosopivirus P14 is an efficient RNA silencing suppressor that binds double-stranded RNAs without size specificity. J. Virol., 79, 7217–7226.
23. Hall, A.H., Wan, J., Shaughnessy, E.E., Ramsay, S.W. and Alexander, K.A. (2004) RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res., 32, 5991–6000.
24. Porter, K.W., Briley, J.D. and Shaw, B.R. (1997) Direct PCR sequencing with boronated nucleotides. Nucleic Acids Res., 25, 1611–1617.
25. He, K. and Ramsay Shaw, B. (1999) Diastereomers of 5′-O-Adenosyl 3′-O-Uridyl Boronophosphate [Up(H3)P]; Synthesis and Nuclease Resistant Property. In Proceedings of the Symposium on RNA Biology III: RNA, Tool and Target in Nucleic Acids Symposium, Research Triangle Park, NC, USA. Oxford University Press, Oxford, UK, Vol. Series No. 41, pp. 99–100.
26. Shaw, B.R., Dobrikov, M., Wang, X., Wen, J., He, K., Lin, J.L., Li, P., Raitv, I., Sergueeva, Z.A. and Sergueev, D. (2003) Reading, writing, and modulating genetic information with boranophosphate mimics of nucleotides, DNA, and RNA. Adv. in Viro Res., 1002, 12–29.
27. Lati, S.M., Ozero, N.D., He, K., Sergueeev, Z.A., Shaw, B.R. and Burke, D.H. (2002) Boron-containing aptamers to ATP. Nucleic Acids Res., 30, 1401–1407.
28. He, K. (2000) Synthesis and properties of Boranophosphate Nucleic Acids. Ph.D. dissertation. Duke University, Durham, NC.
29. Hall, I.H., Bamham, B.S., Rajendran, K.G., Chen, S.Y., Sood, A., Spielvogel, B.F. and Shih, B.H. (1993) Hypolipidemic activity of boronated nucleosides and nucleotides in rodents. Biomed. Pharmacother., 47, 79–87.
30. Li, H., Hardin, C. and Ramsay Shaw, B. (1996) Hydrolysis of thymidine boranomonophosphate and stepwise deuterium substitution of the borane hydrogens. 31P and 11B NMR studies. J. Am. Chem. Soc., 118, 6606–6614.
31. Bartel,D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.
32. Doench,J.G., Petersen,C.P. and Sharp,P.A. (2003) siRNAs can function as miRNAs. Genes Dev., 17, 438–442.
33. Hutvagner,G., McLachlan,J., Pasquinelli,A.E., Balint,E., Tuschl,T. and Zamore,P.D. (2001) A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science, 293, 834–838.
34. Wu,H., MacLeod,A.R., Lima,W.F. and Crooke,S.T. (1998) Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J. Biol. Chem., 273, 2532–2542.
35. Meister,G., Landthaler,M., Patkaniowska,A., Dorsett,Y., Teng,G. and Tuschl,T. (2004) Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell, 15, 185–197.
36. Elbashir,S.M., Martinez,J., Patkaniowska,A., Lendeckel,W. and Tuschl,T. (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J., 20, 6877–6888.
37. Chiu,Y.L. and Rana,T.M. (2003) siRNA function in RNAi: a chemical modification analysis. RNA, 9, 1034–1048.
38. Layzer,J.M., McCaffrey,A.P., Tanner,A.K., Huang,Z., Kay,M.A. and Sullenger,B.A. (2004) In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766–771.
39. Summers,J.S. and Shaw,B.R. (2001) Boranophosphates as mimics of natural phosphodiesters in DNA. Curr. Med. Chem., 8, 1147–1155.
40. Wan,J. (2005) Enzymatic synthesis, properties, and functions of Boranophosphate RNA. Ph.D. dissertation. Duke University, Durham, NC.
41. Parker,J.S., Roe,S.M. and Barford,D. (2005) Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature, 434, 663–666.
42. Chiu,Y.L. and Rana,T.M. (2002) RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell, 10, 549–561.
43. Kim,D.H., Longo,M., Han,Y., Lundberg,P., Cantin,E. and Rossi,J.J. (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol., 22, 321–325.
44. Elmen,J., Thonberg,H., Ljungberg,K., Frieden,M., Westergaard,M., Xu,Y., Wahren,B., Liang,Z., Orum,H., Koch,T. et al. (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res., 33, 439–447.